Literature DB >> 7608739

Macrophage inflammatory protein-1 alpha in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological diseases.

R Miyagishi1, S Kikuchi, T Fukazawa, K Tashiro.   

Abstract

The level of macrophage inflammatory protein-1 alpha (MIP-1 alpha), a newly discovered cytokine of chemokine family, was determined in cerebrospinal fluid (CSF) from 18 patients with multiple sclerosis (MS) and from control patients with other neurological disorders by an enzyme-linked immunosorbent assay (ELISA). The concentration of MIP-1 alpha in CSF was significantly elevated in MS in relapse (4.4 pg/ml) compared with non-inflammatory neurological disease control samples (0.3 pg/ml) (p < 0.0002). These concentrations in MS patients correlated well with leukocyte cell counts and protein content in CSF (r = 0.845, p < 0.0001; r = 0.853, p < 0.0001, respectively). In other inflammatory neurological disorders such as Behçet's disease and HTLV-1 associated myelopathy, significantly increased CSF levels of MIP-1 alpha were also observed. Chemokines are reported to play an important role in an early event of inflammation such as lymphocyte traffic. This report is the first study which confirmed the involvement of a chemokine in MS and other inflammatory neurological disorders.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7608739     DOI: 10.1016/0022-510x(95)00004-l

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  24 in total

Review 1.  Chemokines and central nervous system disorders.

Authors:  W J Karpus
Journal:  J Neurovirol       Date:  2001-12       Impact factor: 2.643

Review 2.  Slit proteins, potential endogenous modulators of inflammation.

Authors:  Necat Havlioglu; Liya Yuan; Hao Tang; Jane Y Wu
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

3.  Macrophage inflammatory protein-1alpha (MIP-1alpha), MIP-1beta, and RANTES mRNA semiquantification and protein expression in active demyelinating multiple sclerosis (MS) lesions.

Authors:  L A Boven; L Montagne; H S Nottet; C J De Groot
Journal:  Clin Exp Immunol       Date:  2000-11       Impact factor: 4.330

Review 4.  Chemokines and glial cells: a complex network in the central nervous system.

Authors:  Elena Ambrosini; Francesca Aloisi
Journal:  Neurochem Res       Date:  2004-05       Impact factor: 3.996

5.  Elevated levels of beta-chemokines in bronchoalveolar lavage fluid (BALF) of individuals infected with human T lymphotropic virus type-1 (HTLV-1).

Authors:  M Seki; J I Kadota; Y Higashiyama; K Iida; T Iwashita; E Sasaki; S Maesaki; K Tomono; S Kohno
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

Review 6.  The multifaceted profile of activated microglia.

Authors:  Marina A Lynch
Journal:  Mol Neurobiol       Date:  2009-07-23       Impact factor: 5.590

7.  Expression of chemokines in the CSF and correlation with clinical disease activity in patients with multiple sclerosis.

Authors:  D J Mahad; S J L Howell; M N Woodroofe
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-04       Impact factor: 10.154

8.  CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions.

Authors:  K E Balashov; J B Rottman; H L Weiner; W W Hancock
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

9.  CC chemokines mediate leukocyte trafficking into the central nervous system during murine neurocysticercosis: role of gamma delta T cells in amplification of the host immune response.

Authors:  Astrid E Cardona; Paula A Gonzalez; Judy M Teale
Journal:  Infect Immun       Date:  2003-05       Impact factor: 3.441

10.  Multiple regulatory domains of IRF-5 control activation, cellular localization, and induction of chemokines that mediate recruitment of T lymphocytes.

Authors:  Betsy J Barnes; Merrill J Kellum; Ann E Field; Paula M Pitha
Journal:  Mol Cell Biol       Date:  2002-08       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.